NEW YORK and CLEVELAND, Feb. 21, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...

NEW YORK and CLEVELAND, Feb. 12, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...

First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB. ABO-101 is well tolerated and demonstrates early ...

First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB. ABO-101 is well tolerated and demonstrates early ...

Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Abeona Therapeutics, Inc. Here are 5 ETFs with the largest exposure to ABEO-US. Comparing the performance and risk of Abeona Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)

NEW YORK and CLEVELAND, Dec. 20, 2017-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, ...

For the 86th time since the 2016 presidential election, the Dow Jones industrial average closed at a record high on Monday, December 18th. This means that 34% of all trading sessions in 2017 closed at new highs and there are still eight trading days left in the year (251 total trading days in 2017). Source: Shutterstock

The Dallas-based company said it had a loss of 13 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...